Herpes zoster
Conditions
Interventions
Experimental group :Plasma therapy apparatus assisted treatment
control group:He-Ne Lasers assisted treatment
Sponsors
The Second Affiliated Hospital of Anhui Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1) Patients aged between 18 and 75, both sexes; 2) Patients diagnosed with herpes zoster who had blisters within 7 days and had obvious blisters; 3) The subjects understood the process and signed the informed consent voluntarily.
Exclusion criteria
Exclusion criteria: 1) Special types of herpes zoster were excluded, such as herpes zoster of the eye, herpes zoster of the ear, herpes zoster of the thoracic type, herpes zoster without eruption, herpes zoster of the rash manifested as blood blisters, herpes zoster of the central nervous system invading the cerebral parenchyma and meninges, herpes zoster of the visceral type, disseminated herpes zoster and herpes zoster of bullosa, hemorrhagic, gangrenous, etc. Patients with pustule and wound infection were excluded. 2) Suffering from severe infectious diseases: diseases in which pathogenic microorganisms grow and multiply in the body, causing an organ or systemic infection and resulting in functional failure or death of the organ or multiple organs of the whole body; 3) Have a serious heart condition: meet one of the following criteria ?. New York Heart Society (NYHA) cardiac function scale (see Appendix I for details) Grade ? to ? heart disease; (2) The Canadian Cardiovascular Society angina Scale (see Appendix II for details) Grade ? to ?, did not respond to conventional drug therapy and/or revascularization; ?. Unstable angina pectoris; 4) Severe brain disease; 5) Severe lung disease: One of the following conditions is met ?. The degree of pulmonary ventilation dysfunction (see Appendix III for details) was graded as moderate to severe; (2) Severe impairment of pulmonary dispersion function (see Appendix IV for details); 6) Users of other medical electrical equipment, including implantable cardiac pacemaker, artificial heart-lung machine, and portable ECG measuring equipment; 7) Patients with acute suppurative inflammation; 8) People with mental illness or severe cognitive impairment; 9) Allergic constitution: allergic history such as laser and acyclovir; 10) Human immunodeficiency virus (HIV) infection 1. Patients using systemic immunosuppressants, patients using biological agents, and patients with malignant tumors; 11) Liver and kidney dysfunction (alanine aminotransferase, aspartate aminotransferase, blood urea or urea nitrogen, blood creatinine more than 2 times the upper limit of normal value); 12) Pregnant and lactating women; 13) Patients who had received antiviral therapy, oral glucocorticoids, and analgesics in the previous week; 14) Patients who participated in clinical trials of any drug and/or medical device within 1 month prior to enrollment; 15) The investigator considers the presence of any other factors that may be inappropriate for inclusion or influence participants' participation in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| effective rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Treatment time;effective rate;Start time of scab;Scab rate;VAS, visual analogue scale;QoL, quality of life score; | — |
Countries
China
Contacts
Public ContactChunjun Yang
The Second Affiliated Hospital of Anhui Medical University
Outcome results
None listed